PLEASANTON, Calif., Sept. 26 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today six scientific presentations at the upcoming IDSA meeting on October 6, 2007. The data will cover the consistency in multiple species of JuvImmune immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.
“We are pleased that the company and its collaborators are presenting a number of high quality papers at the IDSA meeting in San Diego,” said Martin D. Cleary, Co-founder, Chairman and CEO of Juvaris. “We believe these presentations demonstrate the wide applicability of the Juvaris JuvImmune and JuvaVax vaccine platforms for prophylaxis and treatment of infectious disease.”
About Juvaris
Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.
When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs.
The Company recently completed a Series A financing with Kleiner Perkins Caufield & Byers as the sole investor. It plans to start two clinical studies in 2008. The first will be a prophylactic vaccine for Influenza A and the second a therapy for chronic Hepatitis C.
The Company encourages investment and partnering inquiries and can be reached at its website @ http://www.juvaris.com.
Company Contact: Martin D. Cleary Juvaris BioTherapeutics, Inc. 925.399.6200 mdcleary@juvaris.com
Juvaris BioTherapeutics, Inc.
CONTACT: Martin D. Cleary of Juvaris BioTherapeutics, Inc.,+1-925-399-6200, mdcleary@juvaris.com
Web site: http://www.juvaris.com//
